Tag Archives: More

ASCO 2019: What to watch for, including Keytruda, Lynparza, KRAS and more

CHICAGO—As the year’s largest cancer confab, the American Society of Clinical Oncology annual meeting features more new data than any one person could hope to absorb—and more than we could hope to cover. We’re breaking down the highlights below to give you a glimpse at the top studies we’re tracking, so you can follow along,… Read More »